Ovarian hyperstimulation syndrome: Aetiology, prevention and management

Reviews in Gynaecological and Perinatal Practice

Volumn 6, Issue 1-2, 2006, Pages 26-32

  Davis, Michelle ^a   Kennedy, Richard ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Aetiology; IVF; Management; OHSS; Prevention

Indexed keywords

ALBUMIN; ANGIOTENSIN; CHORIONIC GONADOTROPIN; DIURETIC AGENT; DOCARPAMINE; DOPAMINE; ESTRADIOL; GONADORELIN DERIVATIVE; HETASTARCH; HISTAMINE; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROGESTERONE; PROSTAGLANDIN; RECOMBINANT LUTEINIZING HORMONE; RENIN; STEROID; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANAPHYLACTIC SHOCK; ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL; COMPRESSION THERAPY; CRYOPRESERVATION; DISEASE SEVERITY; DRUG WITHDRAWAL; EXTRAVASCULAR SPACE; FEMALE; FERTILIZATION IN VITRO; FEVER; FLUID THERAPY; HOSPITAL ADMISSION; HUMAN; IMMUNE SYSTEM; INFERTILITY THERAPY; INTENSIVE CARE; INTRAVASCULAR SPACE; OVARIECTOMY; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PARACENTESIS; PATHOGENESIS; PATIENT MONITORING; PRION; PRION DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SHUNTING; SYMPTOM; THORACOCENTESIS; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VIRUS INFECTION;

EID: 33646169432     PISSN: 18712320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rigapp.2005.12.004     Document Type: Article

References (61)

1. MacDougall M.J., Tan S.L., and Jacobs H.S. In-vitro fertilisation and the ovarian hyperstimulation syndrome. Hum Reprod 7 (1992) 597-600
2. D'Angelo A., Davies R., Saleh E., Nix B., and Amso N. Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study. Fertil Steril 81 2 (2004) 332-336
3. Delvigne A., and Rovenberg S. Epidemiology of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 8 6 (2002) 559-577
4. Whelan J.G., and Vlahos N.F. The ovarian hyperstimulation syndrome. Fertil Steril 73 5 (2000) 883-896
5. Revel A., Barak V., Lavy Y., et al. Characterisation of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril 66 (1996) 66-71
6. Mathur R.S., Jenkins J.M., and Bansal A.S. The possible role of the immune system in the aetiopathogenesis of ovarian hyperstimulation syndrome. Hum Reprod 12 12 (1997) 2629-2634
7. Brinsden P.R., Wada I., Tan S.L., Balen A., and Jacobs H.S. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. BJOG 102 (1995) 767-772
8. Barak V., Elchalal U., Edelstein M., Kalickman I., Lewin A., and Abramov Y. Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertil Steril 82 2 (2004) 415-420
9. Abramov Y., Schenker J.G., Lewin A., et al. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod 11 7 (1996) 1381-1386
10. McElhinney B., and McClure N. Ovarian hyperstimulation syndrome. Bailliere's Clin Obstet Gynaecol 14 1 (2000) 103-122
11. Elchalal U., and Schenker J.G. The pathophysiology of ovarian hyperstimulation syndrome-views and ideas. Hum Reprod 12 6 (1997) 1129-1137
12. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev 18 1 (1997) 4-25
13. Molskness T.A., Stouffer R.L., Burry K.A., Gorrill M.J., Lee D.M., and Patton P.E. Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and-2, and angiogenin during ovarian stimulation in non-human primates and women. Hum Reprod 19 4 (2004) 822-830
14. McClure N., Healy D., Rogers P.A.W., et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344 (1994) 235-236
15. McElhinney B., Ardill J., Caldwell C., and McClure N. Preventing ovarian hyperstimulation syndrome by inhibiting the effects of vascular endothelial growth factor. J Reprod Med 48 4 (2003) 243-246
16. McElhinney B., Ardill J., Caldwell C., Lloyd F., and McClure N. Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others?. Hum Reprod 17 6 (2002) 1548-1553
17. Paulson R.J., Do Y.S., Hsueh W.A., Eggena P., and Lobo R.A. Ovarian renin production in vitro and in vivo: characterisation and clinical correlation. Fertil Steril 51 (1989) 634-638
18. Lightman A., Tarlatzis B.C., Rzasa P.J., et al. The ovarian renin-angiotensin system: rennin-like activity and angiotensinII/III immunoreactivity in gonadotrophin-stimulated and unstimulated human follicular fluid. Am J Obstet Gynaecol 156 (1987) 808-816
19. Sealey J.E., Glorioso N., Itskovitz J., and Laragh J.H. Prorenin as a reproductive hormone. New form of the renin system. Am J Med 81 (1986) 1041-1046
20. Teruel M.J.G., Carbonell L.F., Llanos M.C., Parilla J.J., Abad L., and Hernandez I. Hemodynamic state and the role of angiotensin II in ovarian hyperstimulation syndrome in the rabbit. Fertil Steril 77 6 (2002) 1256-1260
21. Morris R.S., Wong I.L., Kirkman E., Gentschein E., and Paulson R.J. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod 10 (1995) 1355-1358
22. Balasch J., Arroyo V., Carmona F., et al. Severe ovarian hyperstimulation syndrome: role of peripheral vasodilatation. Fertil Steril 56 (1991) 1077-1083
23. Balasch J., Arroyo V., Fabregues F., et al. Neurohormonal and haemodynamic changes in severe cases of the ovarian hyperstimulation syndrome. Ann Intern Med 121 (1994) 27-33
24. Delbaere A., Smits G., Olatunbosun O., Pierson R., Vassart G., and Costagliola S. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?. Hum Reprod 19 3 (2004) 486-489
25. Smits G., Olatunbosum O., Delbaere A., et al. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. New Eng J Med 349 8 (2003) 760
26. Mathur R.S., Joels L.A., Akande A.V., and Jenkins J.M. The prevention of ovarian hyperstimulation syndrome. BJOG 103 (1996) 740-746
27. Asch R.H., Li H.P., Balmaceda J.P., Weckstein L.N., and Stone S.C. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 6 (1991) 1365-1399
28. Levinsohn-Tavor O., Friedler S., Schachter M., Raziel A., Strassburger D., and Ron-El R. Coasting-what is the formula?. Hum Reprod 18 5 (2003) 937-940
29. Ulug U., Bahceci M., Erden H.F., Shalev E., and Ben-Shlomo I. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 17 2 (2002) 310-312
30. Wada I., Matson P.L., Troup S.A., et al. Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of developing the ovarian hyperstimulation syndrome. Hum Reprod 7 (1992) 962-966
31. Ferraretti A.P., Gianaroli L., Magli C., et al. Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum Reprod 14 6 (1999) 1457-1460
32. Shaker A.G., Zosmer A., Dean N., et al. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertil Steril 65 5 (1996) 992-996
33. D'Angelo A., and Amso N.N. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 17 11 (2002) 2787-2794
34. Asch R.H., Ivery G., Goldsman M., Frederick J.L., Stone S.C., and Balmaceda J.P. The use of intravenous albumin in patients at high risk for ovarian hyperstimulation syndrome. Hum Reprod 8 7 (1993) 1015-1020
35. Aboulghar M., Evers J.H., and Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. The Cochrane Database of Syst Rev 2 (2002) 10.1002/14651858.CD001302 Art No. CD001302
36. Ben-Chetrit A., Eldar-geva T., Gal M., et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomised placebo-controlled trial. Hum Reprod 16 9 (2001) 1880-1884
37. Wilkes M.M., and Navickis R.J. Patient survival after human albumin administration: a meta-analysis of randomised, controlled trials. Annals Int Med 135 3 (2001) 149-164
38. Konig E., Bussen S., Sutterlin M., and Steck T. Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilisation patients: a prospective, randomized, double-blind and placebo-controlled study. Hum Reprod 13 9 (1998) 2421-2424
39. Tan S.L., Balen A., elHussein E., Campbell S., and Jacobs H.S. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomizes study. Fertil Steril 58 2 (1992) 378-383
40. Lainas T., petsas G., Stavropoulou G., Alexopoulou E., Iliadis G., and Minaretziz D. Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Fertil Steril 78 3 (2002) 529-533
41. European Recombinant, LH, Study Group. Human rLH is as effective as, but safer than, urinary hCG in inducing final follicular maturation and ovulation in IVF procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 86 6 (2001) 2607-2618
42. Gonen Y., Balakier H., Powell H., and Casper R.F. Use of gonadotrophin-releasing hormone agonist to trigger follicular maturation for in vitro fertilisation. J Clin Endocrinol Metab 71 4 (1990) 918-922
43. Ben-Arie A., Weissman A., and Shoham Z. Ovarian hyperstimulation: effects of GnRH analogues. Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase. Hum Reprod 11 6 (1996) 1146-1148
44. Daya S., and Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 3 (2004) cd004830
45. National Collaborating Centre for Women's, Children's Health. Fertility: assessment and treatment for people with fertility problems, Clinical Guideline 11. Natl Inst Clin Excell (2004) 104-106
46. Evbuomwan I.O., Davison J.M., and Murdoch A.P. Coexistent hemoconcentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostasis paradox. Fertil Steril 74 1 (2000) 67-72
47. Balasch J., Fabregues F., Arroyo V., Jimenez W., Creus M., and Vanrell J.A. Treatment of severe ovarian hyperstimulation syndrome by a conservative medical approach. Acta Obstet Gynecol Scand 75 (1996) 662-667
48. Al-Khafaji A., and Webb A.R. Fluid resuscitation. Cont Educ Anaesth, Crit Care Pain 4 4 (2004) 127-131
49. Alderson P., Bunn F., Li W.P.A., Li L., Roberts I., and Schierhout G. Human albumin solution for resuscitation and volume expansion in critically ill patients (review). Cochrane Database Syst Rev 4 (2004) CD001208 [The albumin reviewers]
50. Jenkins J.M., Mathur R.S., and Cooke I.D. The management of severe ovarian hyperstimulation syndrome. Brit J Obstet Gynaecol 102 (1995) 2-5
51. Ferraretti A.P., Gianaroli L., Diotallevi L., Festi C., and Trounson A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 7 (1992) 180-183
52. Tsunoda T., Shibahara H., Hirano Y., et al. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecol endocrinol 17 4 (2003) 281-286
53. Koike T., Araki S., Minakami H., et al. Clinical efficacy of peritoneovenous shunting for the treatment of severe ovarian hyperstimulation syndrome. Hum Reprod 15 1 (2000) 113-117
54. Levin I., Almog B., Avni A., Baram A., Lessing J.B., and Gamzu R. Effect of paracentesis of ascitic fluids on urine output and blood indices in patients with severe ovarian hyperstimulation syndrome. Fertil Steril 77 5 (2002) 986-988
55. Maslovitz S., Jaffa A., Eytan O., et al. Renal blood flow alteration after paracentesis in women with ovarian hyperstimulation. Obstet Gynaecol 104 2 (2004) 321-326
56. Aboulghar M.A., Mansour R.T., Serour G.I., and Amin Y. Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril 53 5 (1990) 933-935
57. Aboulghar M., Mansour R.T., and Serour G.I. Management of ascites and pleural effusions in ovarian hyperstimulation syndrome. Fert Steril 64 6 (1995) 1228
58. Stewart J.A., Hamilton P.J., and Murdoch A.P. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 12 10 (1997) 2167-2173
59. Mozes M., Bogokowsky H., Antebi E., et al. Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet 2 (1965) 1213-1215
60. Cluroe A.D., and Synek B.J. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology 27 (1995) 344-346
61. Amarin Z.O. Bilateral partial oophorectomy in the managemtn of severe ovarian hyperstimulation syndrome. Hum Reprod 18 4 (2003) 659-664